Skip Nav Destination
Issues
1 November 2019
-
Cover Image
Cover Image
ABOUT THE COVER
Desmoplasia, hypovascularity, and hypoperfusion work in tandem to prevent antibody therapy of pancreatic adenocarcinoma. In order to disrupt the tumor-stroma interaction and alleviate these factors, Wang and colleagues designed a smoothened inhibitor of sonic hedgehog signaling (NVP-LDE225). In the patient-derived xenograft shown on the cover, NVPLDE225 reduced the number of Ki67+ tumor cells (shown in green). Cell nuclei are counterstained in blue. Taken together, their results demonstrate that NVP-LDE225 dosage for five to ten days primes tumors for treatment with therapeutic antibodies such as cetuximab. Their results rationalize future clinical study of NVP-LDE225 in solid tumors. Read the full article on page 2074. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Reviews
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Nabil F. Saba; Zhuo Gerogia Chen; Missak Haigentz; Paolo Bossi; Alessandra Rinaldo; Juan P. Rodrigo; Antti A. Mäkitie; Robert P. Takes; Primoz Strojan; Jan B. Vermorken; Alfio Ferlito
Small Molecule Therapeutics
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
Anna Capasso; Stacey M. Bagby; Kyrie L. Dailey; Naomi Currimjee; Betelehem W. Yacob; Anastasia Ionkina; Julie G. Frank; Deog Joong Kim; Christina George; Young B. Lee; Ely Benaim; Brian Gittleman; Sarah J. Hartman; Aik Choon Tan; Jihye Kim; Todd M. Pitts; S. Gail Eckhardt; John J. Tentler; Jennifer R. Diamond
Author Choice
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Kerry A. Whalen; Brian H. White; James M. Quinn; Kristina Kriksciukaite; Rossitza Alargova; Tsun P. Au Yeung; Patrick Bazinet; Adam Brockman; Michelle M. DuPont; Haley Oller; James Gifford; Charles-Andre Lemelin; Patrick Lim Soo; Samantha Perino; Benoît Moreau; Gitanjali Sharma; Rajesh Shinde; Beata Sweryda-Krawiec; Mark T. Bilodeau; Richard Wooster
Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia
Niki M. Zacharias; Natalia Baran; Sriram S. Shanmugavelandy; Jaehyuk Lee; Juliana Velez Lujan; Prasanta Dutta; Steven W. Millward; Tianyu Cai; Christopher G. Wood; David Piwnica-Worms; Marina Konopleva; Pratip K. Bhattacharya
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy
Thomas Mühlenberg; Julia Ketzer; Michael C. Heinrich; Susanne Grunewald; Adrian Marino-Enriquez; Marcel Trautmann; Wolfgang Hartmann; Eva Wardelmann; Jürgen Treckmann; Karl Worm; Stefanie Bertram; Thomas Herold; Hans-Ulrich Schildhaus; Hanno Glimm; Albrecht Stenzinger; Benedikt Brors; Peter Horak; Peter Hohenberger; Stefan Fröhling; Jonathan A. Fletcher; Sebastian Bauer
Large Molecule Therapeutics
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Siler H. Panowski; Tracy C. Kuo; Yi Zhang; Amy Chen; Tao Geng; Laura Aschenbrenner; Cris Kamperschroer; Edward Pascua; Wei Chen; Kathy Delaria; Santiago Farias; Marjorie Bateman; Russell G. Dushin; Sherman M. Chin; Thomas J. Van Blarcom; Yik Andy Yeung; Kevin C. Lindquist; Allison G. Chunyk; Bing Kuang; Bora Han; Michael Mirsky; Ingrid Pardo; Bernard Buetow; Thomas G. Martin; Jeffrey L. Wolf; David Shelton; Arvind Rajpal; Pavel Strop; Javier Chaparro-Riggers; Barbra J. Sasu
Author Choice
Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy
Massimo Masiero; Demin Li; Pat Whiteman; Carol Bentley; Jenny Greig; Tasneem Hassanali; Sarah Watts; Stephen Stribbling; Jenna Yates; Ellen Bealing; Ji-Liang Li; Chandramouli Chillakuri; Devon Sheppard; Sébastien Serres; Manuel Sarmiento-Soto; James Larkin; Nicola R. Sibson; Penny A. Handford; Adrian L. Harris; Alison H. Banham
Author Choice
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Elena Burova; Aynur Hermann; Jie Dai; Erica Ullman; Gabor Halasz; Terra Potocky; Seongwon Hong; Matt Liu; Omaira Allbritton; Amy Woodruff; Jerry Pei; Ashique Rafique; William Poueymirou; Joel Martin; Douglas MacDonald; William C. Olson; Andrew Murphy; Ella Ioffe; Gavin Thurston; Markus Mohrs
Cancer Biology and Translational Studies
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation
Anna R. Michmerhuizen; Andrea M. Pesch; Leah Moubadder; Benjamin C. Chandler; Kari Wilder-Romans; Meleah Cameron; Eric Olsen; Dafydd G. Thomas; Amanda Zhang; Nicole Hirsh; Cassandra L. Ritter; Meilan Liu; Shyam Nyati; Lori J. Pierce; Reshma Jagsi; Corey Speers
Author Choice
Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype
Yansong Bian; Yaroslav Teper; Lesley A. Mathews Griner; Taylor J. Aiken; Vivek Shukla; Rajarshi Guha; Paul Shinn; Hong-Wu Xin; Holger Pflicke; Astin S. Powers; Dandan Li; Jian-kang Jiang; Paresma Patel; Steven A. Rogers; Jeffrey Aubé; Marc Ferrer; Craig J. Thomas; Udo Rudloff
COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer
Syed Umbreen; Mudassir Meraj Banday; Anmbreen Jamroze; Adrian P. Mansini; Arsheed A. Ganaie; Marina G. Ferrari; Raihana Maqbool; Firdous H. Beigh; Paari Murugan; Colm Morrissey; Eva Corey; Badrinath R. Konety; Mohammad Saleem
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Aïda Sampera; Francisco Javier Sánchez-Martín; Oriol Arpí; Laura Visa; Mar Iglesias; Sílvia Menéndez; Élisabeth Gaye; Alba Dalmases; Sergi Clavé; Mariona Gelabert-Baldrich; Thomas Tuxen Poulsen; Michael Kragh; Beatriz Bellosillo; Joan Albanell; Ana Rovira; Clara Montagut
eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
Tim Kong; Yibo Xue; Regina Cencic; Xianbing Zhu; Anie Monast; Zheng Fu; Virginie Pilon; Veena Sangwan; Marie-Christine Guiot; William D. Foulkes; John A. Porco, Jr; Morag Park; Jerry Pelletier; Sidong Huang
Models and Technologies
Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Synnøve Nymark Aasen; Heidi Espedal; Christopher Florian Holte; Olivier Keunen; Tine Veronika Karlsen; Olav Tenstad; Zaynah Maherally; Hrvoje Miletic; Tuyen Hoang; Anne Vaag Eikeland; Habib Baghirov; Dag Erlend Olberg; Geoffrey John Pilkington; Gobinda Sarkar; Robert B. Jenkins; Terje Sundstrøm; Rolf Bjerkvig; Frits Thorsen
Correction
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
Sunil Bhakta; Lisa M. Crocker; Yvonne Chen; Meredith Hazen; Melissa M. Schutten; Dongwei Li; Coenraad Kuijl; Rachana Ohri; Fiona Zhong; Kirsten A. Poon; Mary Ann T. Go; Eric Cheng; Robert Piskol; Ron Firestein; Aimee Fourie-O'Donohue; Katherine R. Kozak; Helga Raab; Jo-Anne Hongo; Deepak Sampath; Mark S. Dennis; Richard H. Scheller; Paul Polakis; Jagath R. Junutula
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds